Considering the specificity of the analyzed PERK inhibitor and its minimal impact on normal cells, NCI 159456 could become a potential treatment strategy against NSCLC to improve outcomes for NSCLC patients. This evidence concerns the gene EIF2AK3 and non-small cell lung carcinoma.